10:39 AM
 | 
Jan 18, 2018
 |  BC Innovations  |  Emerging Company Profile

Allogeneic expansion

How Adicet Bio is creating allogeneic therapies with its γδ T cell platform

Rather than taking the conventional approach of starting with autologous therapies, Adicet Bio Inc. is building an allogeneic pipeline from the get-go as part of the charge to make γδ T cells for solid and liquid cancers. The company thinks its ability to isolate and expand multiple subtypes of cell populations into disease-specific cell banks will allow it to create off-the-shelf therapies and avoid the cost and logistical hurdles posed by autologous cells.

The γδ T cell field has been gathering momentum the last few years, as the cells have intrinsic, non-specific targeting and tumor-killing properties lacking in the standard αβ type of T cell used. At least six companies have been formed or announced programs on γδ T...

Read the full 572 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Innovations

Article Purchase

$100 USD
More Info >